<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bozas, G.</style></author><author><style face="normal" font="default" size="100%">Bamias, A.</style></author><author><style face="normal" font="default" size="100%">Koutsoukou, V.</style></author><author><style face="normal" font="default" size="100%">Efstathiou, E.</style></author><author><style face="normal" font="default" size="100%">Gika, D.</style></author><author><style face="normal" font="default" size="100%">Papadimitriou, C.A.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma</style></title><secondary-title><style face="normal" font="default" size="100%">Gynecologic Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Cisplatin</style></keyword><keyword><style  face="normal" font="default" size="100%">Gemcitabine</style></keyword><keyword><style  face="normal" font="default" size="100%">Ovarian cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">refractory</style></keyword><keyword><style  face="normal" font="default" size="100%">Resistant</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33846990923&amp;doi=10.1016%2fj.ygyno.2006.09.006&amp;partnerID=40&amp;md5=6f8285892eb9bf1b9b03bffdc7f4bbbb</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">104</style></volume><pages><style face="normal" font="default" size="100%">580 - 585</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Objectives: Synergism between gemcitabine and cisplatin is supported by preclinical and clinical data. The present study explores the efficacy of a biweekly regimen in platinum-resistant/refractory, paclitaxel-pretreated ovarian and peritoneal cancer. Methods: 50 paclitaxel-pretreated patients with platinum-resistant/refractory ovarian or peritoneal carcinoma who had previously received paclitaxel chemotherapy, were treated with six cycles of gemcitabine 1000 mg/m2 followed by cisplatin 40 mg/m2 on days 1 and 15, repeated every 4 weeks. Results: The median platinum-free interval (PFI) was 4 months while the median number of previous treatment lines was 2. Chemotherapy was well tolerated. Objective responses were observed in 31.5% of evaluable patients (n = 35). CA125 response was observed in 68% of patients with elevated CA125 (n = 41). Median overall survival (OS) was 13.2 months (95% Confidence Interval, CI: 10.2-16.2) while progression-free survival (PFS) was 4.9 months (95%CI: 3.5-6.4). A PFI of less than 3 months was associated with lower objective response rates (15.8% versus 50%, p = 0.03). Conclusions: Biweekly gemcitabine and cisplatin is feasible for patients with platinum-resistant ovarian or peritoneal cancer and is associated with a favorable toxicity profile. In a population with recent exposure to platinum, a PFI of less than 3 months was the major factor influencing response to chemotherapy. © 2007 Elsevier Inc. All rights reserved.</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><notes><style face="normal" font="default" size="100%">Cited By :19Export Date: 21 February 2017</style></notes></record></records></xml>